Oncocyte (NASDAQ:IMDX) Shares Down 3.4% – What’s Next?

Oncocyte Corp (NASDAQ:IMDX) shares traded down 3.4% on Thursday . The stock traded as low as $6.55 and last traded at $6.62. 41,627 shares were traded during mid-day trading, an increase of 5% from the average session volume of 39,722 shares. The stock had previously closed at $6.85.

Analysts Set New Price Targets

A number of brokerages have recently commented on IMDX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncocyte in a research report on Monday, December 29th. Wall Street Zen upgraded Oncocyte to a “hold” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Oncocyte has an average rating of “Sell”.

Oncocyte Stock Up 0.3%

The stock has a market capitalization of $190.30 million, a price-to-earnings ratio of -2.35 and a beta of 1.11.

Oncocyte (NASDAQ:IMDX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter. The firm had revenue of $0.26 million for the quarter. Oncocyte had a negative net margin of 1,380.69% and a negative return on equity of 983.30%.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.